Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2017 | 2012
Number of items: 3.

2017

Janne, Pasi, Van den Heuvel, Michel, Barlesi, Fabrice, Cobo, Manuel, Mazieres, Julien, Crino, Lucio, Orlov, Sergey, Blackhall, Fiona, Wolf, Juergen, Garrido, Pilar, Mariani, Gabriella, Poltoratskiy, Artem, Ghiorghiu, Dana, Mckeown, Astrid, Kilgour, Elaine, Angell, Helen, Smith, Paul, Kohlmann, Alexander, Lawrence, David, Bowen, Karin and Vansteenkiste, Johan (2017). Impact of PD-L1 Status on Clinical Response in SELECT-1: Selumetinib plus Docetaxel in KRASm Advanced NSCLC. J. Thorac. Oncol., 12 (1). S. S952 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Janne, Pasi A., van den Heuvel, Michel M., Barlesi, Fabrice, Cobo, Manuel, Mazieres, Julien, Crino, Lucio, Orlov, Sergey ORCID: 0000-0001-6080-8042, Blackhall, Fiona ORCID: 0000-0001-8716-3395, Wolf, Juergen, Garrido, Pilar, Poltoratskiy, Artem, Mariani, Gabriella, Ghiorghiu, Dana, Kilgour, Elaine, Smith, Paul, Kohlmann, Alexander, Carlile, David J., Lawrence, David, Bowen, Karin and Vansteenkiste, Johan (2017). Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer The SELECT-1 Randomized Clinical Trial. JAMA-J. Am. Med. Assoc., 317 (18). S. 1844 - 1854. CHICAGO: AMER MEDICAL ASSOC. ISSN 1538-3598

2012

Zhang, Jingchuan, Zhang, Lin, Su, Xinying, Li, Ming, Xie, Liang, Malchers, Florian, Fan, ShuQiong, Yin, XiaoLu, Xu, YanPing, Liu, Kunji, Dong, Zhengwei, Zhu, Guanshan, Qian, Ziliang, Tang, Lili, Zhan, Ping, Ji, Qunsheng, Kilgour, Elaine, Smith, Paul D., Brooks, A. Nigel, Thomas, Roman K. and Gavine, Paul R. (2012). Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non-Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models. Clin. Cancer Res., 18 (24). S. 6658 - 6668. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1557-3265

This list was generated on Fri Mar 29 09:56:14 2024 CET.